Correspondence 0001493152-23-013681 from CancerVAX, Inc. (CIK 0001905495)
CancerVAX, Inc. (CIK 0001905495)
Date: April 26, 2023 · CIK: 0001905495 · Accession: 0001493152-23-013681
AI Filing Summary & Sentiment
File numbers found in text: 024-12130
Letter
Re: CancerVax, Inc.
April 26, 2023
United States Securities and Exchange Commission
Attn: Arzhang Navai and Laura Crotty
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Offering Statement on Form 1-A
File No. 024-12130
Ladies and Gentlemen:
CancerVax, Inc (the “CancerVax” or the “Company”) has filed Amendment No. 3 to its Offering Statemetn on Form 1-A as of even date herewith (the “Amendment”). The changes in the Amendment include the addition of the audited financial statements for the year ended December 31, 2022 and the addition of clarification of details about the financial terms of the offering.
Thank you for your assistance and review. Please contact our legal counsel, Callie Jones, at 801-303-5721 with further comments or questions.
Sincerely,
CancerVax,
Inc.
Show Raw Text
CORRESP
1
filename1.htm
April
26, 2023
United
States Securities and Exchange Commission
Attn:
Arzhang Navai and Laura Crotty
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Re:
CancerVax,
Inc.
Offering
Statement on Form 1-A
File
No. 024-12130
Ladies
and Gentlemen:
CancerVax,
Inc (the “CancerVax” or the “Company”) has filed Amendment No. 3 to its Offering Statemetn on Form 1-A as of
even date herewith (the “Amendment”). The changes in the Amendment include the addition of the audited financial statements
for the year ended December 31, 2022 and the addition of clarification of details about the financial terms of the offering.
Thank
you for your assistance and review. Please contact our legal counsel, Callie Jones, at 801-303-5721 with further comments or questions.
Sincerely,
CancerVax,
Inc.
/s/
Ryan Davies
Ryan
Davies
CEO
and Director